---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-032401"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2024-03-08T23:59:59+00:00"
generated_at: "2026-06-05T00:34:01.664839+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Avenue Therapeutics stockholders approve reverse stock split in range 30:1 to 75:1

## Summary
- Majority of voting power executed written consent on March 6, 2024, approving reverse stock split.
- Board authorized to determine exact ratio between 30-for-1 and 75-for-1.
- Holders of approximately 56% of voting power signed consent.
- Schedule 14C information statement to be filed with SEC and sent to stockholders.

## SEC filing metadata
- accession: 0001104659-24-032401
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2024-03-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000110465924032401/0001104659-24-032401-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000110465924032401/tm248309d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-032401
- JSON: https://secwatch.observer/filing/0001104659-24-032401.json
- Plain text: https://secwatch.observer/filing/0001104659-24-032401.txt

## Key facts
- Shareholder Votes
  AVENUE THERAPEUTICS, INC. shareholders approved Reverse stock split within a range of between 30-for-1 and 75-for-1 at the 2024-03-06 meeting.
  - Proposal: reverse split
  - Outcome: passed
  - Meeting: 2024-03-06
  source text: Effective March 6, 2024, the holders of a majority of the voting power of the capital stock of Avenue Therapeutics, Inc. (the “ Company ”) executed a written consent approving a grant of discretionary authority to the board of directors of the Company (the “ Board ”) to, without further stockholder approval, effect a reverse stock split of the Company’s issued and outstanding common stock within a range of between 30-for-1 and 75-for-1 (with the Board being authorized to determinate the exact ratio) (the “ Reverse Stock Split ”) by filing an amendment (the “ Amendment ”) to the Company’s Third Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1644963/000110465924032401/0001104659-24-032401-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.